Stockscreener 앱 받기
1.06
6.00%
0.06
시간 외 거래:
1.09
0.03
+2.83%
전일 마감가:
$1.00
열려 있는:
$1.02
하루 거래량:
382.82K
Relative Volume:
0.28
시가총액:
$17.55M
수익:
-
순이익/손실:
$-12.78M
주가수익비율:
-
EPS:
-
순현금흐름:
$-4.71M
1주 성능:
-5.36%
1개월 성능:
-16.21%
6개월 성능:
+44.81%
1년 성능:
+1.92%
1일 변동 폭
$1.00
$1.09
1주일 범위
$0.98
$1.16
52주 변동 폭
$0.51
$5.01
Mira Pharmaceuticals Inc Stock (MIRA) Company Profile
명칭
Mira Pharmaceuticals Inc
전화
813-369-5150
주소
1200 BRICKELL AVENUE, MIAMI
MIRA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MIRA
Mira Pharmaceuticals Inc
|
1.06 | 17.55M | 0 | -12.78M | -4.71M | -0.8815 |
|
LLY
Lilly Eli Co
|
767.76 | 690.46B | 40.86B | 8.37B | -2.28B | 9.25 |
|
NVO
Novo Nordisk Adr
|
85.00 | 377.54B | 39.36B | 13.79B | 9.83B | 3.086 |
|
JNJ
Johnson Johnson
|
144.47 | 347.83B | 87.70B | 14.68B | 19.03B | 6.05 |
|
ABBV
Abbvie Inc
|
175.58 | 310.27B | 55.53B | 5.12B | 15.62B | 2.88 |
|
MRK
Merck Co Inc
|
98.05 | 248.03B | 63.17B | 12.15B | 14.84B | 4.77 |
Mira Pharmaceuticals Inc 주식(MIRA)의 최신 뉴스
MIRA Pharmaceuticals Submits IND for Ketamir-2, Targeting Unmet Needs in Neuropathic Pain Treatment - Barchart
Grain Spreads: Profit Taking Theme - Barchart
Stocks Rally On Dovish PCE Inflation Report - Barchart
Gilead Stock Gains 15.4% In A Year: Should You Buy, Sell Or Hold? - Barchart
Is Alexandria Real Estate Stock Underperforming The Nasdaq? - Barchart
Is W.R. Berkley Stock Outperforming The Dow? - Barchart
PayPal Rises 40% In A Year: To Buy Or Not To Buy The PYPL Stock? - Barchart
Arabica Coffee Recovers On Weaker Dollar And Smaller Brazilian Crop - Barchart
Medtronic Stock Declines 5.6% In A Month: Time To Buy The Dip? - Barchart
Stocks Regain Footing On Dovish PCE Inflation Report - Barchart
Enterprise Products Stock Rises 25% YTD: Should You Buy Now Or Avoid It? - Barchart
Knightscope K7 Alpha Testing Underway And 2024 Recap - Barchart
Take-Two (NASDAQ:TTWO): Strongest Q3 Results From The Video Gaming Group - Barchart
Stocks Pare Losses on Dovish PCE Report, But Threats Remain from Triple-Witching and Government Shutdown - Barchart
Q3 Video Conferencing Earnings: Five9 (NASDAQ:FIVN) Earns Top Marks - Barchart
Rude Faces Holiday Volatility Amid Fed Policy, G-7 Sanction Talks, And Lower Liquidity - Barchart
Crude Faces Holiday Volatility Amid Fed Policy, G-7 Sanction Talks, And Lower Liquidity - Barchart
C3.ai Stock: Buy, Sell, Or Steer Clear? - Barchart
Federal Reserve's Preferred Inflation Gauge Shows Price Pressures Eased Last Month - Barchart
MIRA Pharmaceuticals Submits IND for Ketamir-2 to FDA, Marking a Significant Milestone in the Company's Pipeline Development - AccessWire
MIRA Pharmaceuticals Submits FDA Application for Breakthrough Pain Treatment Targeting $3.1B Market - StockTitan
EXCLUSIVE: MIRA Pharmaceuticals Files FDA Application To Start Human Trials For Its Lead Pain Treatment - Benzinga
AI’s Next Big Winners: 3 Small-Cap Stocks To Watch In 2025 - Barchart
1 'Strong Buy' Penny Stock With 259% Upside Potential - Barchart
4 Big Drug Stocks That May Continue To Outperform In 2025 - Barchart
Will SentinelOne Stock Break Out In 2025? - Barchart
Should You Buy Bitcoin Below $115,000? - Barchart
Should You Buy Palantir Before Dec. 23? - Barchart
Meet the Dow Jones' Top Performing Stock This Year. It's Climbed 2,300% Over the Past 5 Years, and Its Biggest Catalyst May Be Just Ahead. - Barchart
Wall Street's 3 Favorite Auto Stocks Worth Buying For 2025 - Barchart
This AI Stock Could Get Supercharged In 2025 Thanks To Apple - Barchart
Below-Average Rainfall In Brazil Supports Coffee Prices - Barchart
Is Super Micro Stock A Buy, Sell, Or Hold Amidst Nasdaq Troubles? - Barchart
MIRA Pharmaceuticals (NASDAQ:MIRA) Validates Ketamir-2’s Safety Profile with No Adverse Findings, Paving the Way for IND Submission by Year-End - Defense World
MIRA Pharmaceuticals Validates Ketamir-2's Safety Profile With No Adverse Findings, Paving the Way for IND Submission by Year-End - Brazosport Facts
MIRA Pharmaceuticals' Novel Ketamine Drug Aces Preclinical Safety Tests, Phase I Trials Set for 2025 - StockTitan
EXCLUSIVE: MIRA Pharmaceuticals Validates Ketamir-2's Safety Profile, Paving Way For Human Trials In Neuropathic Pain - Yahoo Finance
Stocks Settle Lower Ahead Of US Inflation News - Barchart
Marvell Technology (NASDAQ:MRVL) Delivers Strong Q3 Numbers, Stock Soars - Barchart
Altimmune Stock Up More Than 25% In A Month: Here's Why - Barchart
A Look Back at Large-format Grocery & General Merchandise Retailer Stocks’ Q3 Earnings: Walmart (NYSE:WMT) Vs The Rest Of The Pack - Barchart
1 Standout Stock To Buy At A Discount After Strong Earnings - Barchart
Walmart becomes the latestand biggestcompany to pull back back on diversity, equity and inclusion initiatives - Barchart
NVDA Stock Looks Cheap To Value Buyers Based On Its Huge FCF Margins - Barchart
Stocks Rally On The Prospects Of Trump’s Business-Friendly Policies - Barchart
Mira Pharmaceuticals appoints new board member By Investing.com - Investing.com Australia
Mira Pharmaceuticals appoints new board member - Investing.com India
MIRA Pharmaceuticals Appoints New Board Member and Chairman - TipRanks
MIRA Reveals Innovative Phase I/IIa Protocol Design and Selection of Clinical Trial Site - AccessWire
Buy Nvidia's Stock For Another Leg Higher As Q3 Earnings Approach? - Barchart
2 Cybersecurity Stocks To Buy And Hold For 2025 - Barchart
Mira Pharmaceuticals Inc (MIRA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.83%
1.48%
자본화:
|
볼륨(24시간):